Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low high-density lipoprotein cholesterol

European Journal of Endocrinology

Volumn 158, Issue 1, 2008, Pages 53-60

  Dullaart, Robin P F ^a   Groen, Albert K ^b   Dallinga Thie, Geesje M ^b   de Vries, Rindert ^a   Sluiter, Wim J ^a   van Tol, Arie ^a,c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN A; APOLIPOPROTEIN B; APOLIPOPROTEIN E; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; PHOSPHOLIPID TRANSFER PROTEIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; CELL FUNCTION; CELL METABOLISM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIABETIC DIET; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE DURATION; FEMALE; FIBROBLAST; HUMAN; HUMAN CELL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIPLE LINEAR REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SEX DIFFERENCE;

AGED; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; BIOLOGICAL TRANSPORT; CELLS, CULTURED; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL ESTERS; CHOLESTEROL, HDL; FEMALE; FIBROBLASTS; HUMANS; LINEAR MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHOSPHOLIPID TRANSFER PROTEINS; PLASMA;

EID: 38949124448     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/EJE-07-0451     Document Type: Article

References (50)

1. Kahn R, Buse J, Ferrannini E & Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005 28 2289-2304.
2. World Health Organisation. Expert Committee on diabetes mellitus: definition, diagnosis, and classification of Diabetes Mellitus and its complications. Report WHO 1999.
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Journal of the American Medical Association 2001 285 2486-2497.
4. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr & Lenfant C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004 109 433-438.
5. Alberti KG, Zimmet P & Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005 366 1059-1062.
6. Ford ES. Risks for alt-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005 28 1769-1778.
7. Qiao Q & the Decode study group, Comparison of different definitions of the metabolic syndrome in relation to cardiovascular mortality in European men and women. Diabetologia 2006 49 2837-2846.
8. Fielding CJ & Fielding PE. Molecular physiology of reverse cholesterol transport. Journal of Lipid Research 1995 36 211-228.
9. Tall AR. An overview of reverse cholesterol transport. European Heart Journal 1998 19 A31-A35.
10. Von Eckardstein A, Nofer JR & Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arteriosclerosis, Thrombosis, and Vascular Biology 2001 21 13-27.
11. Rothblat GH, Llera-Moya M, Atger V, Kellner-Weibel G, Williams DL & Phillips MC. Cell cholesterol efflux: integration of old and new observations provides new insights. Journal of Lipid Research 1999 40 781-796.
12. Yancey PC, Bortnick AE, Kellner-Weibel G, De la Llera-Moya M, Phillips MC & Rothblat CH. Importance of different Pathways of cellular cholesterol efflux. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 712-719.
13. Wang N, Lan D, Chen W. Matsuura F & Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. PNAS 2004 101 9774-9779.
14. Gelissen IC, Harris M, Rye KA, Quinn C, Brown AJ, Kockx M, Cartland S, Packianathan M, Kritharides L & Jessup W, ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-1. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 534-540.
15. Favari E, Lee M, Calabresi L, Franceschini G, Zimetti F, Bernini F & Kovanen PT. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter Al- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. Journal of Biological Chemistry 2004 279 9930-9936.
16. Rye KA & Barter PJ. Formation and metabolism of prebetamigrating, lipid-poor apolipoprotein A-1. Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 421-428.
17. Borggreve SE, De Vries R & Dullaart RPF. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. European Journal of Clinical Investigation 2003 33 1051-1069.
18. Ji J, Watts GF, Johnson AG, Chan DC, Ooi EM, Rye KA, Serone AP & Barrett PH. High-density lipoprotein (HDL) transport in the metabolic syndrome: application of a new model for HDL particle kinetics. Journal of Clinical Endocrinology and Metabolism 2006 91 973-979.
19. Verges B, Petit JM, Duvillard L, Dautin G, Florentin E, Galland F & Gambert P. Adiponectin is an important determinant of apoA-1 catabolism. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 1364-1369.
20. de Vries R, Kerstens MN, Sluiter M, Groen AK, van Tol A & Dullaart RPF. Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia 2005 48 1105-1113.
21. Duong M, Collins HL, Jin W, Zanotti I, Favari E & Rothblat CH. Relative contributions of ABCA 1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 541-547.
22. Alenezi MY, Marcil M, Blank D, Sherman M & Genest J Jr. Is the decreased high-density lipoprotein cholesterol in the metabolic syndrome due to cellular lipid efflux defect? Journal of Clinical Endocrinology and Metabolism 2004 89 761-764.
23. Kiss RS, Kavaslar N, Okuhira K, Freeman MW, Walter S, Milne RW, McPherson R & Marcel YL. Genetic etiology of isolated low HDL syndrome: incidence and heterogeneity of efflux defects. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 1139-1145.
24. Fournier N, Francone O, Rothblat G, Goudouneche D, Cambillau M, Kellner-Weibel G, Robinet P, Royer L, Moatti N, Simon A & Paul JL. Enhanced efflux of cholesterol from ABCA1- expressing macrophages to serum from type IV hypertriglyceridemic subjects. Atherosclerosis 2003 171 287-293.
25. Dullaart RPF & van Tol A. Rote of phospholipid transfer protein and prebeta-high density lipoproteins in maintaining cholesterol efflux from Fu5AH cells to plasma from insulin-resistant subjects. Scandinavian Journal of Clinical and Laboratory Investigation 2001 61 69-74.
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
27. Van Haperen R, van Tol A, Venmeulen P, Jauhiainen M, van Gent T, Van den Berg P, Ehnholm S, Grosveld F, Van der Kamp A & De Crom R. Human plasma phospholipid transfer protein increases the antiatherogenic potential of high density lipoproteins in transgenic mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2000 20 1082-1088.
28. Speijer H, Grocner JEM, van Ramshorst E & van Tol A. Different locations of cholesteryl ester transfer protein and phospholipid transfer protein activities in plasma. Atherosclerosis 1991 90 159-168.
29. Dullaart RPF, Riemens SC, Scheek LM & van Tol A. Insulin decreases plasma cholesteryl ester transfer but not cholesterol esterification in healthy subjects as well as in normotriglyceridaemic patients with type 2 diabetes. European Journal of Clinical Investigation 1999 29 663-671.
30. Hovingh GK, van Wijland MJ, Brownlie A, Bisoendial RJ, Hayden MR, Kastelein JJ & Groen AK. The role of the ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemia. Journal of Lipid Research 2003 44 1251-1255.
31. Boadu E, Choi HY, Lee DW, Waddington El, Chan T, Asztalos B, Vance JE, Chan A, Castro G & Francis GA. Correction of apolipoprotein A-I-mediated lipid efflux and high density lipoprotein particle formation in human Niemann-Pick type C disease fibroblasts. Journal of Biological Chemistry 2006 281 37081-37090.
32. Oram JF, Wolfbauer G, Vaughan AM, Tang C & Albers JJ. Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter Al and enhances cholesterol efflux from cells. Journal of Biological Chemistry 2003 278 52379-52385.
33. Czarnecka H & Yokoyama S. Regulation of cellular cholesterol efflux by lecithin: cholesterol acyltransferase reaction through nonspecific lipid exchange. Journal of Biological Chemistry 1996 271 2023-2028.
34. Matsuura F, Wang N, Chen W, Jiang XC & Tall AR. HDL from CETP-deficient subjects shows, enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. Journal of Clinical Investigation 2006 116 1435-1442.
35. Kaser S, Sandhofer A, Föger B, Ebenbichler CF, Igclseder B, Malaimare L, Paulweber B & Patsch JR. Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia 2001 44 1111-1117.
36. Jonkers IJ, Smelt AH, Hattori H, Scheek LM, van Gent T, De Man FH, Van der Laarse A & van Tol A. Decreased PLTP mass but elevated PLTP activity linked to insulin resistance in HTG: effects of bezafibrate therapy, Journal of Lipid Research 2003 44 1462-1469.
37. Fielding CJ & Fielding PE. Regulation of human plasma lecithin:cholesterol acyltransferase activity by lipoprotein acceptor cholesteryl ester content. Journal of Biological Chemistry 1981 256 2102-2104.
38. Ishida BY, Frolich J & Fielding CJ. Prebeta-migrating high density lipoprotein: quantitation in normal and hyperlipidemic plasma by solid phase radioimmunoassay following electrophoretic transfer. Journal of Lipid Research 1987 28 778-786.
39. Neary R, Bhatnagar D, Durrington P, Ishola M, Arrol S & Mackness M. An investigation of the role of lecithin:cholesterol acyltransferase and triglyceride-rich lipoproteins in the metabolism of pre-beta high density lipoproteins. Atherosclerosis 1991 89 35-48.
40. O'Kane MJ, Wisdom GB, McEneny J, McFerran NV & Trimble ER. Pre-beta high-density lipoprotein determined by immunoblotting with chemiluminescent detection. Clinical Chemistry 1992 38 2273-2277.
41. 1-high-density lipoprotein increases in coronary artery disease. Clinical Chemistry 1996 42 1992-1995.
42. O'Connor PM, Zysow BR, Schoenhaus SA, Ishida BY, Kunitake ST, Naya-Vigne JM, Duchateau PN, Redberg RF, Spencer SJ, Mark S, Mazur M, Heilbron DC, Jaffe RE, Malloy MJ & Kane JP. Prebeta-1 HDL in plasma of normolipidemic individuals: influences of plasma lipoproteins, age, and gender. Journal of Lipid Research 1998 39 670-678.
43. Watanabe H, Soderlund S, Soro-Paavonen A, Hiukka A, Leinonen E, Alagona C, Salonen R, Tuomainen TP, Ehnholm C, Jauhiainen M & Taskinen MR. Decreased high-density lipoprotein (HDL) particle size, prebeta, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intimamedia thickness. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 897-902.
44. Chetiveaux M, Ouguerram K, Zair Y, Maugere P, Falconi I, Nazih H & Krempf M. New model for kinetic studies of HDL metabolism in humans. European Journal of Clinical Investigation 2004 34 262-267.
45. Asztalos BF, Horvath KV, Kajinami K, Nartsupha C, Cox CE, Batista M, Schaefer EJ, Inazu A & Mabuchi H. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. Journal of Lipid Research 2004 45 448-455.
46. de Vries R, Dallinga-Thie GM, Smit AJ, Wolffenbuttel BHR, van Tol A & Dullaart RPF. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus. Diabetologia 2006 49 398-404.
47. Schlitt A, Bickel C, Thumma P, Blankeriberg S, Rupprecht HJ, Meyer J & Jiang XC. High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology 2003 23 1857-1862.
48. de Vries R, Perton FG, Dallinga-Thie GM, van Roon AM, Wolffenbuttel BHR, van Tol A & Dullaart RPF. Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes 2005 54 3554-3559.
49. Boekholdt SM, Kuivenhoven JA, Wareham NJ, Peters RJ, Jukema JW, Luben R, Bingham SA, Day NE, Kastelein JJ & Khaw KT. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation 2004 110 1418-1423.
50. Dullaart RP, Dallinga-Thie GM, Wolffenbuttel BH & van Tol A. CETP inhibition in cardiovascular risk management: a critical appraisal. European Journal of Clinical Investigation 2007 37 90-98.